Home
News
Create
Screeners
Insights
Ishita Drugs & Indus
80.
90
-80.90
(-100.00%)
Market Cap
₹24.20 Cr
PE Ratio
27.24
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-100.00%
1M
-100.00%
6M
-100.00%
1Y
-100.00%
5Y
-100.00%
View Company Insights
Latest news about Ishita Drugs & Indus
Ishita Drugs & Industries: Related Party Makes Second Share Acquisition
Feb 27, 2026
Ishita Pharmaceuticals, a related party of Ishita Drugs & Industries Ltd, made a second share acquisition of 390 equity shares through open market purchase on February 26, 2026. This increased their total holding to 32,642 shares representing 1.09% of the company's equity, up from the previous 1.08% stake.
Ishita Drugs and Industries Limited Files SEBI Disclosure for Substantial Acquisition
Feb 14, 2026
Ishita Drugs Q3FY26 Results: Revenue Falls 24% to ₹313.62 Lakhs
Feb 07, 2026
Ishita Drugs & Industries Ltd Schedules Board Meeting on February 07, 2026 for Q3FY26 Financial Results
Jan 30, 2026
Ishita Drugs & Industries Promoter Jagdish Agrawal Acquires Additional 254 Shares
Dec 31, 2025
More news about Ishita Drugs & Indus
10
Dec 25
Ishita Pharmaceuticals Increases Stake in Ishita Drugs & Industries to 1.02%
Ishita Pharmaceuticals has increased its stake in Ishita Drugs & Industries to 1.02% through an additional acquisition of 560 shares worth Rs. 10.00 each on December 08, 2025. This follows earlier investments, bringing the total holding to 30,550 shares from the previous 29,990 shares, representing continued strategic interest between the related pharmaceutical companies.
11
Nov 25
Ishita Drugs & Industries Reports Mixed Q2 Results, Progresses on Facility Upgrade
Ishita Drugs & Industries Limited reported Q2 FY2026 revenue of Rs. 806.81 lakhs, up from Rs. 692.92 lakhs in Q1. However, net profit declined to Rs. 14.33 lakhs from Rs. 30.23 lakhs. The company is upgrading its manufacturing facility to comply with Revised Schedule M regulations, with Rs. 50 lakhs spent on civil construction. The project faced delays due to extended monsoon. The company maintains a strong liquidity position with Rs. 472.68 lakhs in cash and bank balances.
Ishita Drugs & Indus
80.
90
-
80.
90
(-
100.
00
%)
1 Year Returns:
-100.00%
Industry Peers
Sun Pharmaceutical
1,801.60
(-
1.
30
%)
Divis Laboratories
6,071.00
(-
3.
36
%)
Torrent Pharmaceuticals
4,390.00
(-
1.
26
%)
Dr Reddys Laboratories
1,292.30
(-
2.
02
%)
Cipla
1,314.70
(-
0.
72
%)
Lupin
2,314.90
(-
1.
80
%)
Zydus Life Science
905.90
(-
1.
20
%)
Mankind Pharma
2,138.90
(-
3.
13
%)
Aurobindo Pharma
1,296.50
(-
1.
17
%)
Alkem Laboratories
5,355.50
(-
1.
63
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO